SAN DIEGO, Jan. 25, 2016 /PRNewswire/ -- American Life Sciences Pharmaceuticals, Inc. (ALSP) (www.alspinc.com), a privately held company focused on therapeutics for Traumatic Brain Injury (TBI) and Alzheimer's Disease (AD) announced that its recent research findings will be presented this week at the Keystone TBI Conference.
Vivian Hook, Ph.D., UCSD, will be speaking January 27 in the morning session entitled "From Precision Medicine to Therapies (TBI)". Her talk, "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury", will review evidence that cathepsin B is an important drug target for TBI and present a case for a global role for cathepsin B in neurodegenerative disease. A related poster can be seen on Monday afternoon.
Gregory Hook, PhD, ALSP, will present the poster "E64d, a Cysteine Protease Inhibitor, Provides a Viable Translational Opportunity for Development of Therapeutics for TBI" on Monday afternoon, reviewing small molecule cysteine protease inhibitors shown to be effective in a number of TBI-related animal models and describing the selection of a lead clinical candidate.
Michael D. Pierschbacher, Ph.D., CEO, ALSP, stated "we are confident that the high profile our work is receiving in this venue bodes well for our TBI program as we advance this year in our quest to develop a disease-modifying therapeutic that will improve outcomes for patients impacted by TBI for whom there are no FDA-approved treatments now available".
ALSP is a privately held San Diego company developing small molecule drugs that target key brain enzymes, called neuroproteases, for treating neurodegenerative diseases, initially focused on TBI and AD.
TBI affects millions of Americans each year and can cause a range of debilitating symptoms. TBI increases the risk for long-term neurodegenerative conditions such as AD.
About Cathepsin B
Cathepsin B is a cysteine protease that has is substantially increased in a variety of neurological disorders. Gene knockout studies in mouse models have shown it to be a key cause of neuromuscular dysfunction, memory loss, inflammation, increased pro-necrotic and pro-apoptotic peptides and neuronal death resulting from TBI.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws.
Contact: Leslie Barrett, Investor Relations, firstname.lastname@example.org, 415-531-4618
SOURCE American Life Sciences Pharmaceuticals, Inc.